IAG’s CEO will Give a Keynote Lecture at the 8th World Congress on Immunology
IAG’s CEO is invited to give a keynote lecture at the 8th World Congress on Immunology, London, 11-12 March 2019 titled ‘Precision i/o Clinical Trial: Leveraging Technology to Gain Insight into Treatment Efficacy’.
Dr. Olga Kubassova, industry innovator and proponent of the use of modern technologies and methodologies in clinical development will speak how clinical development paradigm in immunology is changing and what modern technologies can offer in a way to accelerate go / no-go decisions in early trials.
The conference brings together researchers and businesses interested in immunology from around the world; it will host a number of scientific and technical sessions on cutting edge research and latest research innovations in the field of Immunology and biomedical sciences.
Olga’s second talk is titled ‘Three types of artificial intelligence (AI) to impact clinical research in the next 3 years’. It will highlight how integrating multi-parametric imaging such as MRI and novel methodologies for imaging data assessment can impact clinical development of inflammatory arthritis and other auto-immune diseases, including Rheumatoid Arthritis, Psoriatic Arthritis, Lupus and Inflammatory Bowel Disease.
About the Conference:
Immunology World 2019 will provide the platform to meet global leaders in immunology and relevant fields to hear their research at this exclusive scientific program. The Immunology Conference hosting presentations from editorial board members of prominent refereed journals, renowned and active investigators and decision makers in the field of Immunology. Immunology World 2019 Organizing Committee also invites Young investigators at every career stage to submit abstracts reporting their latest scientific findings in oral and poster sessions. https://immunology.cmesociety.com/renowned_speakers
About Image Analysis Group (IAG)
IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.
Learn more: www.ia-grp.com
Reach out: firstname.lastname@example.org
Follow the Company: Linkedin